Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 in glucocorticoid refractory/dependent chronic GVHD
NCT04944043Phase 2Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rovadicitinib in chronic graft-versus-host disease (cGVHD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximal Tolerable Dose at 4 weeks, Recommended Phase II Dose at 4 weeks and 1 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
rovadicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04944043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944043.